The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study
Abstract The benefit of prostate cancer screening is counterbalanced by the risk of overdiagnosis and overtreatment. The use of a multi-parametric magnetic resonance imaging (mpMRI) test after a positive prostate-specific antigen (PSA) test followed by magnetic resonance imaging-guided biopsy (MRIGB...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-01-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-021-81459-2 |
| _version_ | 1831637942252077056 |
|---|---|
| author | Abraham M. Getaneh Eveline A. M. Heijnsdijk Harry J. de Koning |
| author_facet | Abraham M. Getaneh Eveline A. M. Heijnsdijk Harry J. de Koning |
| author_sort | Abraham M. Getaneh |
| collection | DOAJ |
| description | Abstract The benefit of prostate cancer screening is counterbalanced by the risk of overdiagnosis and overtreatment. The use of a multi-parametric magnetic resonance imaging (mpMRI) test after a positive prostate-specific antigen (PSA) test followed by magnetic resonance imaging-guided biopsy (MRIGB) may reduce these harms. The aim of this study was to determine the effects of mpMRI and MRIGB vs the regular screening pathway in a population-based prostate cancer screening setting. A micro-simulation model was used to predict the effects of regular PSA screening (men with elevated PSA followed by TRUSGB) and MRI based screening (men with elevated PSA followed by mpMRI and MRIGB). We predicted reduction of overdiagnosis, harm-benefit ratio (overdiagnosis per cancer death averted), reduction in number of biopsies, detection of clinically significant cancer, prostate cancer death averted, life-years gained (LYG), and quality adjusted life years (QALYs) gained for both strategies. A univariate sensitivity analysis and threshold analysis were performed to assess uncertainty around the test sensitivity parameters used in the MRI strategy.In the MRI pathway, we predicted a 43% reduction in the risk of overdiagnosis, compared to the regular pathway. Similarly a lower harm-benefit ratio (overdiagnosis per cancer death averted) was predicted for this strategy compared to the regular screening pathway (1.0 vs 1.8 respectively). Prostate cancer mortality reduction, LY and QALYs gained were also slightly increased in the MRI pathway than the regular screening pathway. Furthermore, 30% of men with a positive PSA test could avoid a biopsy as compared to the regular screening pathway. Compared to regular PSA screening, the use of mpMRI as a triage test followed by MRIGB can substantially reduce the risk of overdiagnosis and improve the harm-benefit balance, while maximizing prostate cancer mortality reduction and QALYs gained. |
| first_indexed | 2024-12-19T07:01:31Z |
| format | Article |
| id | doaj.art-91d99c51764245b8bc4729d0188fb589 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-19T07:01:31Z |
| publishDate | 2021-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-91d99c51764245b8bc4729d0188fb5892022-12-21T20:31:24ZengNature PortfolioScientific Reports2045-23222021-01-011111810.1038/s41598-021-81459-2The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling studyAbraham M. Getaneh0Eveline A. M. Heijnsdijk1Harry J. de Koning2Department of Public Health, Erasmus MC, University Medical Center RotterdamDepartment of Public Health, Erasmus MC, University Medical Center RotterdamDepartment of Public Health, Erasmus MC, University Medical Center RotterdamAbstract The benefit of prostate cancer screening is counterbalanced by the risk of overdiagnosis and overtreatment. The use of a multi-parametric magnetic resonance imaging (mpMRI) test after a positive prostate-specific antigen (PSA) test followed by magnetic resonance imaging-guided biopsy (MRIGB) may reduce these harms. The aim of this study was to determine the effects of mpMRI and MRIGB vs the regular screening pathway in a population-based prostate cancer screening setting. A micro-simulation model was used to predict the effects of regular PSA screening (men with elevated PSA followed by TRUSGB) and MRI based screening (men with elevated PSA followed by mpMRI and MRIGB). We predicted reduction of overdiagnosis, harm-benefit ratio (overdiagnosis per cancer death averted), reduction in number of biopsies, detection of clinically significant cancer, prostate cancer death averted, life-years gained (LYG), and quality adjusted life years (QALYs) gained for both strategies. A univariate sensitivity analysis and threshold analysis were performed to assess uncertainty around the test sensitivity parameters used in the MRI strategy.In the MRI pathway, we predicted a 43% reduction in the risk of overdiagnosis, compared to the regular pathway. Similarly a lower harm-benefit ratio (overdiagnosis per cancer death averted) was predicted for this strategy compared to the regular screening pathway (1.0 vs 1.8 respectively). Prostate cancer mortality reduction, LY and QALYs gained were also slightly increased in the MRI pathway than the regular screening pathway. Furthermore, 30% of men with a positive PSA test could avoid a biopsy as compared to the regular screening pathway. Compared to regular PSA screening, the use of mpMRI as a triage test followed by MRIGB can substantially reduce the risk of overdiagnosis and improve the harm-benefit balance, while maximizing prostate cancer mortality reduction and QALYs gained.https://doi.org/10.1038/s41598-021-81459-2 |
| spellingShingle | Abraham M. Getaneh Eveline A. M. Heijnsdijk Harry J. de Koning The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study Scientific Reports |
| title | The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study |
| title_full | The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study |
| title_fullStr | The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study |
| title_full_unstemmed | The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study |
| title_short | The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study |
| title_sort | comparative effectiveness of mpmri and mri guided biopsy vs regular biopsy in a population based psa testing a modeling study |
| url | https://doi.org/10.1038/s41598-021-81459-2 |
| work_keys_str_mv | AT abrahammgetaneh thecomparativeeffectivenessofmpmriandmriguidedbiopsyvsregularbiopsyinapopulationbasedpsatestingamodelingstudy AT evelineamheijnsdijk thecomparativeeffectivenessofmpmriandmriguidedbiopsyvsregularbiopsyinapopulationbasedpsatestingamodelingstudy AT harryjdekoning thecomparativeeffectivenessofmpmriandmriguidedbiopsyvsregularbiopsyinapopulationbasedpsatestingamodelingstudy AT abrahammgetaneh comparativeeffectivenessofmpmriandmriguidedbiopsyvsregularbiopsyinapopulationbasedpsatestingamodelingstudy AT evelineamheijnsdijk comparativeeffectivenessofmpmriandmriguidedbiopsyvsregularbiopsyinapopulationbasedpsatestingamodelingstudy AT harryjdekoning comparativeeffectivenessofmpmriandmriguidedbiopsyvsregularbiopsyinapopulationbasedpsatestingamodelingstudy |